NCT02834013 2026-06-03Nivolumab and Ipilimumab in Treating Patients With Rare TumorsNational Cancer Institute (NCI)Phase 2 Active not recruiting798 enrolled
NCT05407441 2026-04-13Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def TumorsDana-Farber Cancer InstitutePhase 1/2 Active not recruiting49 enrolled